Source: CME Online 2013



Rating:

Share or cite this content

Citations should be made in the following way:
A. Wells
K. Antoniou. New treatment strategies in Interstitial Lung disease. CME Online 2013

Member's Comments

No comment yet.

Related content which might interest you: The incidence of Progressive Fibrotic Interstitial Lung Diseases (PFILD) treatable with oral-antifibrotic therapy in a UK Specialist Interstitial Lung Disease clinic. Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Identifying Inflammatory Myopathies to optimise Interstitial lung disease treatment strategies> Source: International Congress 2017 – Novel and old entities Year: 2017 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Childhood interstitial lung disease: A diagnostic challenge Source: International Congress 2015 – Connective tissue disorders Year: 2015 Mindfulness-based stress reduction in patients with interstitial lung disease: A pilot study Source: International Congress 2014 – ILDs 3 Year: 2014 Desquamative interstitial pneumonia in a Danish cohort, treatment response and outcome Source: International Congress 2014 – ILDs 2 Year: 2014 Clinical effect of pirfenidone on incidence of lung carcinoma in chronic interstitial pneumonia Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014 Lymphangioleiomyomatosis in TOSCA - TuberOus SClerosis registry to increAse disease awareness Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Analysis of children’s diffuse parenchymal lung disease from the European Management Platform for Childhood Interstitial Lung Diseases: Frequency of disease categories and treatments used Source: International Congress 2017 – Rare diseases Year: 2017 Treatment response in hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases II Year: 2016 Clinical study of pediatric interstitial lung diseases in China Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Effect of pirfenidone on IPF progression Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Pulmonary interstitial glycogenosis: Diagnosis and follow-up Source: International Congress 2016 – Neonatal and paediatric multiorgan manifestations of acute and chronic pulmonary disease and use of treatments Year: 2016